{"id":"NCT00337467","sponsor":"Bristol-Myers Squibb","briefTitle":"Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression","officialTitle":"Phase IIIb Multicenter, Single Arm, Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Maintenance With Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in HIV-Infected Patients Evidencing Virologic Suppression OREY (Only REYataz) Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06","primaryCompletion":"2008-05","completion":"2009-05","firstPosted":"2006-06-16","resultsPosted":"2010-07-19","lastUpdate":"2010-07-19"},"enrollment":61,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Human Immunodeficiency Virus (HIV) Infections"],"interventions":[{"type":"DRUG","name":"Atazanavir + Ritonavir","otherNames":["Reyataz","BMS-232632"]}],"arms":[{"label":"A1","type":"EXPERIMENTAL"}],"summary":"The main purpose is to explore whether atazanavir/ritonavir (ATV/RTV) single enhanced protease inhibitor therapy can maintain virologic suppression without a marked increase in virologic failure.","primaryOutcome":{"measure":"Percentage of Participants With Treatment Failure Through Week 48","timeFrame":"Week 48","effectByArm":[{"arm":"Atazanavir (ATV)/Ritonavir (RTV) Monotherapy","deltaMin":21.3,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":7,"countries":["Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":61},"commonTop":["HYPERCHOLESTEROLAEMIA","HYPERTRIGLYCERIDAEMIA","HEADACHE","RESPIRATORY TRACT INFECTION","DEPRESSION"]}}